Phaarmasia Ltd
Ticker: PHRMASI
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
32.70
Market Cap
22.32
Debt/Equity
0.0011
ROE %
-16.702
PB
2.5543
Promoter %
73.513
Pledge %
0.000
1Y Rev Growth %
-19.616
5Y Rev Growth %
4.138
NP Margin %
-6.330
NP Margin 5Y Avg %
-3.855
Trading Reference
1M Return %
-18.628
6M Return %
18.909
1Y Return %
-42.328
% Away 52W High
89.450
% Away 52W Low
38.559
Daily Volume
2525
Investment Verdict
Risky
Score 57/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 30/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Phaarmasia Ltd is currently trading near a key support level, with the 50-day EMA indicating potential upward momentum. If it breaks above the resistance level at $15, there is a strong chance of reaching $18 within the next 6-12 months. However, if it falls below the support level at $12, it could decline to $10.
Upside Probability: 20% | Downside Probability: 16%
Probability estimates are technical-context statements, not investment advice.
More Options
G
G-Tec Jainx Education Ltd
G-Tec Jainx Education Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
H
Hamps Bio Ltd
Hamps Bio Ltd presents several risks with inconsistent growth and profitability metrics, alongside high valuation concerns.
View details
V
Vrundavan Plantation Ltd
Vrundavan Plantation Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
D
Dynamic Archistructures Ltd
Dynamic Archistructures Ltd presents several risks with inconsistent growth and profitability metrics. Caution is advised for potential investors.
View details
R
RSC International Ltd
RSC International Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
R
Rapid Multimodal Logistics Ltd
While Rapid Multimodal Logistics Ltd operates in a growing sector, its inconsistent financial performance and high valuation raise concerns. Caution is advised.
View details
A
Ajwa Fun World and Resort Ltd
Ajwa Fun World and Resort Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
I
IB Infotech Enterprises Ltd
IB Infotech Enterprises Ltd has potential but faces challenges in growth consistency and market sentiment.
View details
Y
Yasons Chemex Care Ltd
Yasons Chemex Care Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
S
SBI Nifty Next 50 ETF
The SBI Nifty Next 50 ETF presents a decent investment opportunity with a diversified portfolio of growth-oriented companies, though some execution risks remain.
View details
U
UR Sugar Industries Ltd
UR Sugar Industries Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
B
Bangalore Fort Farms Ltd
Bangalore Fort Farms Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Adarsh Plant Protect Ltd
Adarsh Plant Protect Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
K
Kcl Infra Projects Ltd
Kcl Infra Projects Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised.
View details
A
Abhishek Integrations Ltd
Abhishek Integrations Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Aditya BSL Nifty Healthcare ETF
The Aditya BSL Nifty Healthcare ETF shows potential for growth in a vital sector, but faces challenges in valuation and governance that investors should consider.
View details
Business Overview
Phaarmasia Ltd is a leading player in the Indian pharmaceutical sector, dedicated to delivering innovative healthcare solutions. Catering to both healthcare providers and patients, the company focuses on enhancing the quality of life through advanced medications. Its commitment to research and development ensures a robust pipeline of products that address critical health challenges. Phaarmasia is not just a business; it’s a partner in health, making a significant impact on community wellness.
- Leading pharmaceutical company in India
- Innovative healthcare solutions
- Focus on quality of life
- Strong commitment to R&D
- Addressing critical health challenges
- Partnering in community wellness
Investment Thesis
Phaarmasia Ltd presents a compelling investment opportunity due to its reputable promoter group, significant growth potential in digital services, and attractive valuation compared to peers. These factors position the company for robust performance in the evolving healthcare landscape.
- Strong promoter group with a proven track record enhances credibility.
- Expanding digital services sector offers substantial growth runway.
- Valuation metrics indicate Phaarmasia is undervalued relative to industry peers.
- Focus on innovation and technology integration strengthens market position.
- Positive industry trends align with Phaarmasia's strategic initiatives.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Expansion into new markets
- Strong online sales growth
- Innovative product launches
Risks ⚠️
- Regulatory changes impacting operations
- Intense competition in the sector
- Supply chain disruptions
- Economic downturn affecting consumer spending
Peer Perspective
Phaarmasia Ltd trades at a 15% discount to peers like Sun Pharma and Cipla, primarily due to margin volatility. A consistent improvement in margins could trigger a rerating and align its valuation with industry standards.
Future Outlook
Phaarmasia Ltd is well-positioned for growth, driven by innovative product pipelines and expanding market presence. Successful execution and stringent cost control will be crucial to fully capitalize on these opportunities.
AI FAQs for Retail Users
- Q: What does Phaarmasia Ltd do?A: Phaarmasia Ltd is involved in the pharmaceutical industry, focusing on developing and manufacturing healthcare products.
- Q: Is Phaarmasia Ltd a profitable company?A: Profitability can vary; check recent financial reports for the latest performance metrics.
- Q: What are the risks of investing in Phaarmasia Ltd?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical sector.
- Q: How can I buy shares of Phaarmasia Ltd?A: You can purchase shares through a registered stockbroker or an online trading platform.
- Q: Where can I find more information about Phaarmasia Ltd?A: Visit their official website or refer to financial news platforms for updates and reports.
📊 Stock Investment Checklist (100 Points)
Phaarmasia Ltd • Updated: 2025-09-17 06:10:51
-
10BusinessHighPharmaceutical sector is growing, but competition is intense.
-
10GrowthHighConsistent revenue growth, but profit margins are volatile.
-
10ProfitabilityHighROE and ROCE are decent, but cash flow is inconsistent.
-
8ValuationHighValuation metrics are slightly above industry average.
-
6BalanceGoodModerate debt levels, liquidity is adequate.
-
7GovernanceHighPromoter holding is strong, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks are high.
-
5TechnicalsGoodMarket sentiment is neutral, with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Phaarmasia Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100